6-K
Alterity Therapeutics Ltd (ATHE)
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER
PURSUANTTO RULE 13a-16 OR 15d-163
UNDERTHE SECURITIES EXCHANGE ACT OF 1934
Forthe month of September 2025
AlterityTherapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street,Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicateby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
ThisForm 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073,333-248980 and 333-228671)and our Registration Statements on Form F-3 (Files No. 333-274816,333-251647, 333-231417and 333-250076)
ALTERITYTHERAPEUTICS LIMITED
(adevelopment stage enterprise)
The following exhibits are submitted:
| 99.1 | Date of AGM and Closing Date for Director Nominations |
|---|
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | |
|---|---|
| By: | /s/ Geoffrey P. Kempler |
| Geoffrey P. Kempler | |
| Chairman |
Date: September 23, 2025
2
Exhibit 99.1
23 September 2025
ASX Announcement
DATE OF AGM AND CLOSING DATE FOR DIRECTOR NOMINATIONS
Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) (Alterity or the Company) advises that, in accordance with ASX Listing Rule 3.13.1, its next Annual General Meeting (AGM) will be held at 11.00am (AEDT) on Friday 21 November 2025.
In addition, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Wednesday 1 October 2025. Any nominations must be received in writing no later than 5.00pm (AEST) on Wednesday 1 October 2025 at the Company’s registered office.
Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting, which will be provided to shareholders shortly. The Notice of Meeting will also be available on the ASX Company Announcements Platform and the Company’s website at www.alteritytherapeutics.com.
For further information, please contact:
| /s/ Abby Macnish Niven |
|---|
| Abby Macnish Niven |
| CFO & Company Secretary |
T: +61 3 9349 4906
Alterity TherapeuticsLimited
Suite 4, Level 14, 350Collins Street, Melbourne, VIC 3000 Australia
T: +61 (0)3 9349 4906| www.alteritytherapeutics.com